Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Price Target at $19.67

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.67.

Several research firms recently weighed in on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in TEVA. State Board of Administration of Florida Retirement System lifted its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,018 shares of the company’s stock worth $875,000 after acquiring an additional 7,335 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Teva Pharmaceutical Industries by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after buying an additional 28,071 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at about $166,000. UniSuper Management Pty Ltd lifted its holdings in Teva Pharmaceutical Industries by 109.2% during the 1st quarter. UniSuper Management Pty Ltd now owns 15,900 shares of the company’s stock valued at $224,000 after buying an additional 8,300 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in Teva Pharmaceutical Industries by 25.9% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 480,299 shares of the company’s stock valued at $6,778,000 after buying an additional 98,710 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.59 on Friday. The stock has a market capitalization of $18.79 billion, a price-to-earnings ratio of -19.40, a PEG ratio of 1.33 and a beta of 0.87. The company has a fifty day moving average of $17.65 and a 200 day moving average of $17.36. Teva Pharmaceutical Industries has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.